Announcements Trials
Browse Landscape

Status

Completed 229Recruiting 150Unknown 124Terminated 81Active not recruiting 73Not yet recruiting 48Withdrawn 39Suspended 5Enrolling by invitation 3No longer available 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 8Sarcoma 6Prostatic Neoplasms 6Pancreatic Neoplasms 6Neuroblastoma 6Multiple Myeloma 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Ovarian Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Pheochromocytoma 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Lymphoma, B-Cell × Clear all
NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Regeneron Pharmaceuticals

Available
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡